Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA® (pembrolizumab) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE